Avantor, Inc. (AVTR) Stock Price & Analysis

Avantor, Inc. (AVTR) closed at USD 17.15 on Thursday, October 22, 2026, down 0.64% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 17.26; the Oct 22, 2026 session ranged USD 16.97–17.45 on volume of 12,740,458 shares. Market capitalization is $11.60B, with a 52-week range of USD 7.27–17.45 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AVTR.md

Key facts (AVTR)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AVTR)

USDFY2021FY2022FY2023FY2024FY2025TTM
Revenue$7.39B$7.51B$6.97B$6.78B$6.55B$6.56B
Gross profit$2.50B$2.60B$2.36B$2.28B$2.14B—
Operating income$972M$1.13B$696M$1.08B-$246M-$301M
Net income$573M$687M$321M$712M-$530M-$578M
EPS (diluted)$0.85$1.01$0.47$1.04-$0.78—
Free cash flow$843M$710M$724M$692M$495M$455M
Gross margin33.9%34.6%33.9%33.6%32.7%—
Operating margin13.2%15.0%10.0%16.0%-3.8%-4.6%
Net margin7.8%9.1%4.6%10.5%-8.1%-8.8%
Revenue growth+15.5%+1.7%-7.3%-2.6%-3.4%—
Cash + short-term investments$302M$373M$263M$262M$365M—
Total debt$7.02B$6.29B$5.54B$4.06B$3.95B—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AVTR)

P/S 1.8x · EV/EBITDA 127.8x · EV/Sales 2.3x · P/FCF 25.5x · P/B 2.1x · FCF yield 3.92% · Earnings yield -4.98% · Net debt $3.39B · EV $15.0B

P/E at fiscal year-ends: Dec 2024 20.2x, Dec 2023 48.2x.

Superinvestors (SEC 13F-HR, Q2 2026) (AVTR)

5 of 80 tracked investors hold AVTR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

InvestorFirm% of portfolioValueChange
Greenhaven Associates2.82%$244MAdded +9.0%
Mason HawkinsSoutheastern Asset Management2.44%$46.8MAdded +34.2%
First Pacific Advisors1.02%$81.1MAdded +1.3%
Dodge & Cox FundsDodge & Cox0.62%$1.19BAdded +0.3%
Yacktman Asset Management0.58%$47.2MAdded +0.5%

Insider purchases (SEC Form 4, open-market, last ~7 months) (AVTR)

2 purchases, $287K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Trade dateInsiderRoleSharesValueAvg priceInsider type
2026-05-08Lucier Gregory TDirector10,000$83K8.32Too little history (no open-market trades in 2023–2025)
2026-05-01Dingemans SimonDirector25,000$204K8.14Too little history (no open-market trades in 2023–2025)

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (AVTR)

Consensus Hold (mean 3.00 on a 1–5 scale), 15 analysts; mean target USD 15.5 (low 13, high 19).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-10-13Morgan StanleyTarget raisedEqual-Weight$14 → $15
2026-10-13TD CowenTarget raisedHold$15 → $17
2026-10-07BarclaysTarget raisedUnderweight$13 → $15
2026-09-09UBSTarget raisedNeutral$10.5 → $16
2026-07-30Morgan StanleyTarget raisedEqual-Weight$10 → $14
2026-07-30RBC CapitalTarget raisedSector Perform$9 → $14
2026-07-30StifelTarget raisedHold$8 → $15
2026-07-30Evercore ISI GroupTarget raisedIn-Line$10.5 → $14
2026-07-30Wells FargoTarget raisedOverweight$14 → $16
2026-07-08CitigroupTarget raisedNeutral$9 → $11
2026-07-06Evercore ISI GroupTarget raisedIn-Line$8 → $10.5

Total return (dividends reinvested) (AVTR)

1Y (from 2025-10-23)5Y (from 2021-10-18)
Total return+10.9%-55.4%
S&P 500 (SPY)+14.9%+80.3%
Per year+11.0%-14.9%
Volatility (annualized)51.0%40.9%
Max drawdown-52.1% (Oct 2025→Mar 2026)-82.4% (Dec 2021→Mar 2026)

AVTR revenue by business segment (quarter ended Jun 30, 2026)

LineRevenueShare of totalYoY
VWR Distribution & Services$1.24B73.3%+2.7%
Bioscience & Medtech Products$451.8M26.7%-5.1%
Total revenue$1.69B100%—

AVTR revenue by product line (quarter ended Jun 30, 2026)

LineRevenueShare of totalYoY
Proprietary$880.4M52.0%-1.5%
Third-party$811.9M48.0%+2.8%
Total revenue$1.69B100%—

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

Companies that name AVTR in their SEC reports

Relationship to AVTRCompanyFilingSentence
customerESTABLISHMENT LABS HOLDINGS INC. (ESTA)10-K Feb 27, 2026“In particular, we obtain NuSil brand medical-grade silicone from Avantor, Inc. (formerly NuSil Technology LLC), or Avantor, which is a sole-source supplier of such products to the majority of the silicone breast implant industry.”

AVTR customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 5% of revenue, per the company's 10-K filed Feb 11, 2026. The company does not name it.

AVTR company outlook (results filed Jul 29, 2026)

Quoted word-for-word from the SEC 8-K results press release.

AVTR analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Sep 2026)$0.21$0.20+2.0%$1.64B15
Next quarter (ends Dec 2026)$0.23$0.23-0.9%$1.68B14
Current fiscal year (ends Dec 2026)$0.81$0.79+3.0%$6.59B15
Next fiscal year (ends Dec 2027)$0.88$0.85+2.9%$6.74B15

Key Statistics (as of October 23, 2026 at 09:23 UTC)

PriceUSD 17.15
Change▼ 0.64% (down)
Previous CloseUSD 17.26
OpenUSD 17.29
Day RangeUSD 16.97 – 17.45
52-Week RangeUSD 7.27 – 17.45
Volume12,740,458 shares
Market Cap$11.60B
ExchangeNYQ

Technical Analysis (AVTR)

Nexqual's technical model rates AVTR "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Overall SignalBUY
RSI (14)71.29 (overbought)
vs SMA50Above (USD 15.12)
MACD0.53 (positive)

Analyst Ratings (AVTR)

Wall Street analysts rate AVTR "Hold" based on 15 analysts, with a mean price target of USD 15.5 (range USD 13–19), per Nexqual as of October 23, 2026 at 09:23 UTC.

Consensus RatingHold
Analyst Count15
Mean TargetUSD 15.5
High TargetUSD 19
Low TargetUSD 13
Buy / Hold / Sell2 / 12 / 1

Earnings (AVTR)

Next Earnings Date2026-10-28
EPS EstimateUSD 0.21
Revenue Estimate$1.64B

Recent Earnings History

QuarterActual vs Estimate
2026-06-30USD 0.21 vs est 0.19 ▲ beat
2026-03-31USD 0.17 vs est 0.16 ▲ beat
2025-12-31USD 0.22 vs est 0.22 ▲ beat
2025-09-30USD 0.22 vs est 0.23 ▼ miss

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (AVTR)

Total Revenue$6.56B
Revenue Growth (latest quarter, YoY)+0.50%
Gross Margin+31.82%
Operating Margin+7.16%
Profit Margin-8.81%
ROE-9.70%
Debt / Equity0.66
Current Ratio1.78
Total Cash$306.80M
Total Debt$3.70B

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Ownership (AVTR)

Insider Ownership+1.53%
Institutional Ownership+105.76%
Shares Outstanding676.36M
Float657.81M
Short % of Float+7.06%

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (AVTR)

Avantor, Inc. is led by Emmanuel Ligner, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

President, CEO & DirectorEmmanuel Ligner
President of Laboratory SolutionsCorey D. Walker
Executive Vice President of Bioscience ProductionBenoit Gourdier
Executive VP & CFOTodd W. Garner
Executive VP & COOMary Blenn

Major Backers & Investors (AVTR)

Notable institutional backers of Avantor, Inc. include Dodge & Cox Inc., Greenhaven Associates, Inc., Engine Capital Management, LP, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

InvestorStake
Dodge & Cox Inc.17.75%
Greenhaven Associates, Inc.3.64%
Engine Capital Management, LP2.94%
Barrow, Hanley Mewhinney & Strauss, LLC2.92%
New Mountain Capital, L.L.C.2.07%
Bridge Builder Trust-Bridge Builder Large Cap Value Fund1.61%

Index Funds (Passive)

FundStake
BlackRock10.39%
Vanguard Group9.18%
State Street3.19%
Dimensional Fund Advisors3.02%

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From Avantor, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)

Key Strengths & Strategy (as disclosed to the SEC)

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
COOThe Cooper Companies, Inc.USD 61.65▲ 4.54%
RGENRepligen CorporationUSD 178.71▼ 0.72%
ALGNAlign Technology, Inc.USD 155.51▲ 2.74%
BAXBaxter International Inc.USD 25.65▲ 3.85%
SOLVSolventum CorporationUSD 87.45▲ 0.9%
ATRAptarGroup, Inc.USD 128.1▲ 1.97%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt